Medicare locked into inflated AI device prices for 5 years under new bill

What it does

This bill amends Medicare payment rules to create a special fast-track payment category for AI-based healthcare services (devices cleared by the FDA that use artificial intelligence to help doctors diagnose or treat patients). Manufacturers can submit their own cost data to set initial payment rates, and Medicare must keep these services in the fast-track category for at least 5 years before reassigning them—effectively guaranteeing favorable payment terms and protection from downward rate adjustments during that period. The bill also codifies a policy allowing hospitals to bill Medicare for software-as-a-service costs separately.

Why we flagged it

The bill's operative mechanism is a guaranteed payment floor and rate-protection scheme for AI healthcare devices, funded by Medicare. It is functionally a subsidy to device manufacturers disguised as a payment-classification amendment. The title 'Health Tech Investment Act' obscures that the 'investment' is a public cost borne by Medicare beneficiaries and taxpayers.

• Subsection (b) codifies a separate 2022 policy allowing hospitals to bill Medicare for software-as-a-service costs, unrelated to the bill's core AI-device payment mechanism.

What the text implies

• Manufacturers can embed inflated costs in their initial submissions (invoices, subscriptions, overhead), and Medicare is bound to those figures for 5 years—no downward adjustment even if actual costs prove lower.
• The 5-year lock-in prevents Medicare from using real-world claims data to negotiate lower rates, effectively removing price competition and cost-containment tools during the protection period.
• The definition of 'algorithm-based healthcare service' is expansive and delegated to the Secretary, allowing future regulatory expansion without congressional action.
• Concurrent or adjunctive AI services (performed alongside other procedures) are now eligible for the fast-track category if they 'require additional resources'—a vague standard that may inflate billing for routine diagnostic add-ons.
• The bill codifies a 2022 software-as-a-service policy retroactively (effective 2023), potentially opening claims for back-billing or rate adjustments on services already provided.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and Medicare beneficiaries face higher costs: the bill guarantees favorable payment rates for AI healthcare services based on manufacturer-submitted cost data for at least 5 years, blocking Medicare from reassigning services to lower-cost categories even if claims data later shows overpayment. This shifts negotiating power from Medicare to device manufacturers and locks in inflated rates at public expense.

Who stands to gain

• AI healthcare device manufacturers (e.g., diagnostic AI, clinical decision-support software vendors)
• Hospital outpatient departments (via software-as-a-service billing codification)
• FDA-cleared medical device companies using machine learning or AI

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), Department of Health and Human Services (HHS), Medicare program, Hospital Outpatient Prospective Payment System (OPPS), Ambulatory Payment Classification (APC)

Where it stands

7 cosponsors: 5 Democrats, 2 Republicans.

• Nov 20, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 20, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

15 lobbying clients named this bill on 21 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $8,111,000 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

John Joyce, the sponsor, reported $1,473,437 in PAC receipts in the 2026 cycle. $24,500 of that came from 6 PACs tied to these lobbying clients.

• Philips Holding USA Inc. — $1,950,000 on 3 filings
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing
• Medtronic Inc — $1,180,000 on 1 filing
• Advanced Medical Technology Assn — $971,000 on 1 filing
• Siemens Medical Solutions Usa, Inc — $860,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.